Please login to the form below

Not currently logged in
Email:
Password:

Kane & Finkel closes

Independent agency unable to survive loss of several key accounts
Kane and Finkel logo

The independent healthcare marketing agency Kane & Finkel has shut up shop due to the loss of several key accounts.

The first quarter of 2013 saw the San Francisco-based agency lose three accounts, representing a third of its total business, within a month.

The agency was hit first when the FDA denied approval of Dynavax Technologies' adult hepatitis B vaccine Heplisav. Next, management changes claimed work on Astellas's transplant franchise, and on the launch of an ultra-orphan drug from Raptor Pharmaceuticals.

“It had a cascading effect, and even though we were picking up additional work, it wasn't significant enough to fill in the gap,” said the agency's chief creative officer, Robert Finkel, speaking to Medical Marketing and Media.

“We decided around December to notify employees and clients that we would be winding the business down. We stopped doing new business on February 28. The office is closed.”

The partnership between the two principals, Finkel and managing director John Kane, has been dissolved, and the two will no long work together.

Founded in 1997, Kane & Finkel had a long history of professional work for pharma, biotech and device clients, including UCB Pharma's epilepsy drug Keppra and brands from Astellas, Neutrogena and Merck.

Kane & Finkel served clients across the US, Asia and Europe. At one point, the agency had 75 staff, five of them in a London office opened in 2010.

“We had been very successful, but all the signs were there that we had to move on,” Finkel told MM&M . “I have a lot of pride in what we did. We won many creative awards and built many long-term relationships with clients.”

Finkel expects to stay in healthcare. His new consultancy, RMF Consultancy, has already signed up a number of healthcare clients. John Kane's plans have yet to be announced.

6th May 2014

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete True Life

Complete True Life is a progressive new agency specializing in the validation of insights-led and generation of evidence-based real-world studies...

Latest intelligence

More of the same: The importance of strategic communications planning for biosimilar entry
GCI Health's Hannah Morris considers the importance of strategic communications planning for biosimilar entry, a market anticipated to deliver between €8-26bn in savings across the European Union by 2020....
Online Physician Communities
How can pharma realise the power of digital?
Firstly, by making it owned and driven by the most senior leadership team in the business...
Remapping the market: Does Pharma's global model need a shake up?
For patients, carers and professionals, wherever they are in the world, digital technology is inherent in their everyday lives. Digital is, so to speak, a global language. The success of...